Biotech News

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

RenovoRx (RNXT)RenovoRx2026-06-25 13:46 ESTFDA / regulatory

RNXT (RNXT) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is rnxt.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

RNXTRenovoRx2026-06-25 13:46 EST

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

RNXTRenovoRx2026-06-25 13:46 EST

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

RNXTRenovoRx2026-06-25 13:46 EST

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

RNXTRenovoRx2026-06-25 13:46 EST

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

RNXTRenovoRx2026-06-25 13:46 EST

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

RNXTRenovoRx2026-06-25 13:46 EST

RenovoRx Announces $10 Million at Market Private Placement

RNXTRenovoRx2026-06-25 13:46 EST

RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

RNXTRenovoRx2026-06-25 13:46 EST

RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement

RNXTRenovoRx2026-06-25 13:46 EST

RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

RNXTRenovoRx2026-06-25 13:46 EST

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

View all latest news

RenovoRx

RenovoRx is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

RNXTRenovoRx2026-06-26 07:30 EST

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

RNXTRenovoRx2026-06-26 07:30 EST

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

RNXTRenovoRx2026-06-26 07:30 EST

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

RNXTRenovoRx2026-06-26 07:30 EST

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

RNXTRenovoRx2026-06-26 07:30 EST

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States